Chagas Disease Treatment Market - Insights

Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America, due to migration of people from Latin America to others countries.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/934

For instance, according a study published in National Center for Biotechnology Information (NCBI), in 2015, 4.2% of Latin American living in European countries were chronically affected with Chagas disease. Benznidazole is the only FDA approved treatment indicated for the treatment of Chagas disease. However, the drug, Nifurtimox manufactured by Bayer AG, is in the World Health Organization's (WHO) list of 'Essential Medicines' and used in the treatment of Chagas disease.

Increasing approval to Chagas disease treatment drugs is expected to drive growth of the global Chagas disease treatment market

Benznidazole is an essential antiparasitic drug used for the treatment of Chagas disease. In April 2018, Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved Laboratorio Elea Phoenix SA’s drug benznidazole for pediatric indication used for the treatment of Chagas disease. Currently, Argentina has the highest number of people suffering from Chagas disease. For instance, according to data published by Mundo Sano (Nongovernmental foundation in Argentina), in 2017, around 7,300,000 people were exposed to Chagas disease and about 1,600,000 were infected, in Argentina. Hence, approval of novel drugs is expected to fuel the market growth in the near future. Such approval of Chagas disease treatment drugs is expected to boost growth of Chagas disease treatment market in the near future.

Click To Continue Reading @ https://www.coherentmarketinsights.com/market-insight/chagas-disease-treatment-market-934

The global Chagas treatment disease market was valued at US$ 5.67 Mn in 2016 and is expected to witness a CAGR of 7.3% over the forecast period (2017–2025).

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://healthcaremarketconsulting.blogspot.com/

This release was published on openPR.